Inthelia is a biotechnology company focused on developing innovative therapies that protect and restore the vascular barrier. The company’s mission is to translate cutting-edge science into transformative treatments for diseases driven by endothelial dysfunction, inflammation, and vascular leakage.

By targeting the mechanisms that maintain endothelial integrity and vascular homeostasis, Inthelia aims to prevent the cascade of organ injury that underlies many critical illnesses. Its research spans early discovery through to translational and preclinical development, integrating insights from vascular biology, immunology, and inflammation.

Through strategic collaborations and a commitment to scientific excellence, Inthelia is advancing a new generation of therapeutics designed to stabilize the vascular barrier and improve patient outcomes across a range of acute and chronic conditions.

Why work with us

For General

• Barrier-first science: We specialize in stabilizing the vascular barrier, addressing a root cause of organ injury across acute and chronic diseases.
• Translational focus: Clear line of sight from mechanism to medicine, rigorous models, biomarkers, and clinically relevant endpoints.
• Efficient execution: Lean, milestone-driven development with decisive go/no-go gates to conserve time and capital.
• Collaborative by design: We co-develop with academics, clinicians, and industry to accelerate learning and impact.
• Platform potential: Mechanism-anchored programs with expansion paths across multiple indications involving endothelial dysfunction and inflammation.
• Patient-first ethos: Transparent data, high standards of safety, and outcomes that matter to patients and providers.

For Partners (Biopharma / Academia)

• Plug-in science & assets: Complementary mechanisms and combination potential for barrier protection.
• De-risked translation: Human-relevant models, pharmacodynamic readouts, and partnership-ready studies.
• Flexible structures: Sponsored research, co-development, or licensing—aligned to shared milestones and value creation.

For Investors

• Compelling thesis: Targeting endothelial integrity to intercept multi-organ injury and improve outcomes.
• Capital discipline: Focused pipeline, efficient study design, and clear catalysts.
• Durable upside: Platform with indication stacking, biomarker strategy, and partnering optionality.

For Talent (Careers)

• Mission with meaning: Help prevent organ failure by protecting the body’s vascular barrier.
• High-ownership culture: Small, expert teams with real responsibility and visible impact.
• Growth & mentorship: Work alongside leaders in vascular biology, immunology, and translational medicine.